StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.80+0.10 (+0.60%)

Close on Nov 17, 2026Market cap $3.06BP/E –Yield –

Xeris Biopharma total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Xeris Biopharma's total debt was $252.59M at Jun 30, 2026. For fiscal 2025 it was $220.34M, down 5.1% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$220.34M-5.1%
FY2024Dec 31, 2024$232.11M+21.6%
FY2023Dec 31, 2023$190.93M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$252.59M+15.5%
Q1 FY2026Mar 31, 2026$221.22M-3.7%
Q4 FY2025Dec 31, 2025$220.34M-5.1%
Q3 FY2025Sep 30, 2025$219.47M+1357.6%
Q2 FY2025Jun 30, 2025$218.63M+14.5%
Q1 FY2025Mar 31, 2025$229.76M–
Q4 FY2024Dec 31, 2024$232.11M–
Q3 FY2024Sep 30, 2024$15.06M–
Q4 FY2023Dec 31, 2023$190.93M–

More Xeris Biopharma figures

See a number that looks wrong?